Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MetaVia ( (MTVA) ) has provided an announcement.
On December 2, 2025, MetaVia Inc. announced a 1-for-11 reverse stock split of its common stock, effective December 4, 2025, to comply with Nasdaq’s listing requirements. This decision, approved by the stockholders on June 30, 2025, reduces the number of outstanding shares from approximately 25.4 million to 2.3 million, while maintaining the authorized shares at 100 million. The reverse split will adjust the conversion and exercise prices of stock options and warrants proportionately, with fractional shares being rounded down and compensated in cash. The common stock will continue trading under the symbol ‘MTVA’ with a new CUSIP number.
The most recent analyst rating on (MTVA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.
MetaVia’s overall stock score is heavily impacted by its poor financial performance, characterized by persistent losses and no revenue generation. The technical analysis indicates weak market momentum, and negative valuation metrics highlight the stock’s high-risk profile. Although recent positive trial results provide some potential for future growth, significant strategic changes are necessary for the company to achieve financial stability and investor confidence.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is developing DA-1726 for obesity treatment and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is an oxyntomodulin analogue functioning as a dual agonist for glucagon-like peptide-1 and glucagon receptors, while vanoglipel is a G-protein-coupled receptor 119 agonist promoting the release of key gut peptides.
Average Trading Volume: 2,757,890
Technical Sentiment Signal: Sell
Current Market Cap: $18.18M
Find detailed analytics on MTVA stock on TipRanks’ Stock Analysis page.